What's new

[Cyprus Times] A new drug may treat cases of resistant hypertension

piesometro.jpg

The new drug Baxdrostat can significantly reduce high blood pressure (hypertension) in patients who previously did not respond to existing treatments, a clinical trial by British and American researchers has shown.

The scientists, led by Professor Morris Brown of Queen Mary University of London, who published the paper in the American medical journal New England Journal of Medicine and a similar announcement at an American Heart Association conference, conducted the randomized, controlled and multicenter study with 248 patients over the course of 12 weeks.

Participants were randomly divided into two groups and one took the new drug (once a day at various doses), while the other took a placebo (placebo). At the start of the study all patients had out-of-control blood pressure, even though they had by then taken at least three anti-hypertensive drugs.

At the end of the phase 2 study the Baxdrostat group (at the highest dose of 2 milligrams per day) had shown an average reduction of 20 units in blood pressure (20.3 mm Hg), compared with a reduction of 9 units in the placebo group. No serious side effects of the drug were noted at all. It is the first time, according to the researchers, that a new class of drugs against resistant hypertension has been successfully developed and tested.

The new drug works by preventing the patient's body from producing aldosterone, a hormone that regulates the amount of salts in the body. The reduction in aldosterone levels is seen in both blood and urine. The effectiveness of Baxdrostat is mainly for patients whose resistant hypertension is partly due to their body producing too much aldosterone.

Dr Brown said that the results of this first-of-its-kind drug are exciting, although further study is needed before we can make definitive comparisons with existing drugs. However, Baxdrostat could offer hope to many people who do not respond to traditional treatment for hypertension.

Hypertension is a leading cause of strokes and a common cause of heart attacks, as well as kidney failure. In most patients, the cause of hypertension is unknown and they require lifelong drug therapy.

In recent years, it has been found that 5% to 10% of hypertensive patients have a mutation in their DNA in the adrenal glands that results in them producing excessive amounts of the steroid hormone aldosterone, resulting in the retention of salts in their body and thus increasing blood pressure. It is precisely these hypertensive patients who are most resistant to existing treatments.



Source: APE


Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times

Source
 
Back
Top